SAFETY DATA SHEET

Posaconazole Injection Formulation

SECTION 1. IDENTIFICATION
Product name: Posaconazole Injection Formulation

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Telefax: 908-735-1496
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Skin sensitization: Category 1
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 1 (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs)

GHS label elements
Hazard pictograms:
Signal Word: Danger
Hazard Statements: H317 May cause an allergic skin reaction.
H361d Suspected of damaging the unborn child.
H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Precautionary Statements
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing must not be allowed out of the workplace.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P308 + P313 IF exposed or concerned: Get medical advice/attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P363 Wash contaminated clothing before reuse.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
<td></td>
</tr>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td>beta-Cyclodextrin, sulfobutyl ethers, sodium salts</td>
<td>182410-00-0</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret.

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
- Diarrhea
- Fever
- Headache
- Nausea
- Vomiting
May cause an allergic skin reaction.
### Section 5. Fire-Fighting Measures

<table>
<thead>
<tr>
<th>Protection of first-aiders</th>
<th>Notes to physician</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed.</td>
<td>First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).</td>
</tr>
<tr>
<td>First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).</td>
<td>Treat symptomatically and supportively.</td>
</tr>
</tbody>
</table>

#### Suitable extinguishing media
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

#### Unsuitable extinguishing media
- None known.

#### Specific hazards during firefighting
- Exposure to combustion products may be a hazard to health.

#### Hazardous combustion products
- Carbon oxides
- Sulfur oxides
- Metal oxides

#### Specific extinguishing methods
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

#### Special protective equipment for fire-fighters
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### Section 6. Accidental Release Measures

<table>
<thead>
<tr>
<th>Personal precautions, protective equipment and emergency procedures</th>
<th>Environmental precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.</td>
<td>Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Methods and materials for containment and cleaning up</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to</td>
<td></td>
</tr>
</tbody>
</table>

---

3 / 15
determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Avoid inhalation of vapor or mist.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
<td>TWA</td>
<td>300 µg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection:
- General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn.
- Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air
supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Eye protection
: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
: Work uniform or laboratory coat.

Hygiene measures
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : Colorless to pale yellow

Odor : odorless

Odor Threshold : No data available

pH : 2.6

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available
SAFETY DATA SHEET

Posaconazole Injection Formulation

Vapor pressure : No data available
Relative vapor density : No data available
Relative density : No data available
Density : 1.15 g/cm³
Solubility(ies) Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

- **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**
  - Acute oral toxicity: LD50 (Rat): > 8,800 mg/kg

- **Posaconazole:**
  - Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
  - LD50 (Mouse): > 3,000 mg/kg
  - Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg

Skin corrosion/irritation
- Not classified based on available information.

Components:

- **Posaconazole:**
  - Species: Rabbit
  - Result: No skin irritation

Serious eye damage/eye irritation
- Not classified based on available information.

Components:

- **Posaconazole:**
  - Species: Rabbit
  - Result: Mild eye irritation

Respiratory or skin sensitization

Skin sensitization
- May cause an allergic skin reaction.

Respiratory sensitization
- Not classified based on available information.

Components:

- **.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**
  - Assessment: Probability or evidence of skin sensitization in humans

- **Posaconazole:**
  - Test Type: Magnusson-Kligman-Test
  - Routes of exposure: Skin contact
  - Species: Guinea pig
  - Result: negative
SAFETY DATA SHEET

Posaconazole Injection Formulation

Germ cell mutagenicity

Not classified based on available information.

Components:

Posaconazole:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosomal aberration
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Intravenous
  Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Posaconazole:

Species: Rat
Application Route: oral (feed)
Exposure time: 2 Years
Result: positive
Remarks: The mechanism or mode of action is not relevant in humans.

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
Result: positive
Remarks: The mechanism or mode of action is not relevant in humans.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

.β.-Cyclodextrin, sulfobutyl ethers, sodium salts:

Effects on fertility:
- Test Type: Fertility
  Species: Rat
  Application Route: Intravenous injection
  Result: negative
Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Result: negative

Effects on fertility :
- Test Type: Fertility/early embryonic development
  Species: Rat, male
  General Toxicity Parent: NOAEL: 180 mg/kg body weight
  Symptoms: No effects on mating performance.
  Result: negative

- Test Type: Fertility/early embryonic development
  Species: Rat, female
  General Toxicity Parent: NOAEL: 45 mg/kg body weight
  Symptoms: No effects on mating performance.
  Result: negative

Effects on fetal development :
- Test Type: Embryo-fetal development
  Species: Rat, female
  Application Route: Oral
  Frequency of Treatment: 6 - 15 days
  Developmental Toxicity: LOAEL: 29 mg/kg body weight
  Result: Fetotoxicity., Malformations were observed.

- Test Type: Embryo-fetal development
  Species: Rabbit, female
  Frequency of Treatment: 7 - 19 days
  Developmental Toxicity: LOAEL: 40 mg/kg body weight
  Result: Fetotoxicity.

Reproductive toxicity - Assessment :
- Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Components:

Posaconazole:
- Routes of exposure: Ingestion
- Target Organs: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
- Assessment: Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

**Posaconazole:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>392 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone marrow, Adrenal gland, Lymph nodes, Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>56 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>180 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>12 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood, Gastrointestinal tract, spleen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>8 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Cardio-vascular system, Lungs, Adrenal gland, Blood</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**Posaconazole:**

| Ingestion | Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhea, hypertension, neutropenia, electrolyte imbalance |
### Ecotoxicity

#### Components:

**.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Toxicity</th>
<th>Exposure</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to fish</td>
<td>LC50 (Oncorhynchus mykiss (rainbow trout)): &gt; 220 mg/l</td>
<td>96 h</td>
<td>OECD Test Guideline 203</td>
<td>No toxicity at the limit of solubility.</td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates</td>
<td>EC50 (Daphnia magna (Water flea)): &gt; 96 mg/l</td>
<td>48 h</td>
<td>OECD Test Guideline 202</td>
<td></td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>EC50 (Selenastrum capricornutum (green algae)): &gt; 100 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
<td></td>
</tr>
</tbody>
</table>

**Posaconazole:**

<table>
<thead>
<tr>
<th>Component</th>
<th>Toxicity</th>
<th>Exposure</th>
<th>Method</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to fish</td>
<td>LC50 (Oncorhynchus mykiss (rainbow trout)): &gt; 0.95 mg/l</td>
<td>96 h</td>
<td>OECD Test Guideline 203</td>
<td></td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates</td>
<td>EC50 (Daphnia magna (Water flea)): 0.276 mg/l</td>
<td>48 h</td>
<td>OECD Test Guideline 202</td>
<td></td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 0.509 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
<td>NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l</td>
</tr>
<tr>
<td>Toxicity to fish (Chronic toxicity)</td>
<td>NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l</td>
<td>33 d</td>
<td>OECD Test Guideline 210</td>
<td></td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</td>
<td>NOEC (Daphnia magna (Water flea)): 0.244 mg/l</td>
<td>21 d</td>
<td>OECD Test Guideline 211</td>
<td>Remarks: No toxicity at the limit of solubility.</td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC50 (Natural microorganism): &gt; 1,000 mg/l</td>
<td>3 h</td>
<td>OECD Test Guideline 209</td>
<td>Test Type: Respiration inhibition</td>
</tr>
</tbody>
</table>
Persistence and degradability

Components:

**Posaconazole:**

- Stability in water: Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

**Posaconazole:**

- Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305
- Partition coefficient: n-octanol/water: log Pow: 4.15

Mobility in soil

Components:

**Posaconazole:**

- Distribution among environmental compartments: log Koc: 5.52

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

**UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards
- Respiratory or skin sensitization
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)

SARA 313
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know
Water 7732-18-5
.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts 182410-00-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined
SAFETY DATA SHEET

Posaconazole Injection Formulation

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

<table>
<thead>
<tr>
<th>Health</th>
<th>Flammability</th>
<th>Instability</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Health

Selected Health Hazard statements:
• This substance is toxic by inhalation, ingestion and skin contact.

Flammability

Selected Flammability Hazard statements:
• Flammable gas when exposed to incandescent light or flame.

Instability

Selected Instability Hazard statements:
• hazardous reaction in the presence of oxidising reagents

HMIS® IV:

<table>
<thead>
<tr>
<th>Health</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -
SAFETY DATA SHEET

Posaconazole Injection Formulation

Version 8.0  Revision Date: 09/11/2019  SDS Number: 22519-00015  Date of last issue: 04/24/2019
Date of first issue: 10/16/2014

United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative


Revision Date: 09/11/2019

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8